ROIV · Nasdaq · CIK 0001635088

Roivant Sciences Ltd.

Roivant Sciences Ltd.’s most recent SEC filing in our snapshot is a Form SCHEDULE 13G/A filed on Oct 27, 2026. In fiscal 2026 (year ended Mar 31, 2026) it reported revenue of $8.3M and net income of -$299.8M, according to its XBRL data on EDGAR. Its EDGAR record lists 99 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2026
$8.3M
Net income, FY2026
-$299.8M
Form 4 filings on record, past 12 months
99

Company overview

Legal name (as filed)
Roivant Sciences Ltd.
Ticker
ROIV
SEC Central Index Key (CIK)
0001635088
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
LONDON
State or country of incorporation
Bermuda
Fiscal year ends
March 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#493 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Roivant Sciences Ltd.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$55.3MFY2022$31.5MFY2023$32.7MFY2024$29.1MFY2025$8.3MFY2026
Net income
-$845.3MFY2022-$1.0BFY2023$4.3BFY2024-$172.0MFY2025-$299.8MFY2026
ROIV annual results
ItemFY2022
ended Mar 31, 2022		FY2023
ended Mar 31, 2023		FY2024
ended Mar 31, 2024		FY2025
ended Mar 31, 2025		FY2026
ended Mar 31, 2026
Revenue$55.3M$31.5M$32.7M$29.1M$8.3M
Net income-$845.3M-$1.0B$4.3B-$172.0M-$299.8M
Diluted EPS-$1.26-$1.42$5.23-$0.24-$0.54
Total assets$2.6B$2.4B$7.2B$5.4B$5.7B
Cash and equivalents$2.1B$1.7B$6.5B$2.7B$1.4B

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

ROIV latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
May 20, 202610-KAnnual report· period Mar 31, 2026Document · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 21, 20268-KRegulation FD disclosure· period Oct 21, 2026Document · Index
Jul 29, 2026DEF 14ADefinitive proxy statement· period Sep 16, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Roivant Sciences Ltd., by form type:

4 ×29144 ×68-K ×3SCHEDULE 13G/A ×1SCHEDULE 13D/A ×1
ROIV recent filings
FiledFormWhat it isOriginal
Oct 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Oct 27, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 23, 2026Document · Index
Oct 27, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 23, 2026Document · Index
Oct 27, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 23, 2026Document · Index
Oct 22, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 20, 2026Document · Index
Oct 21, 20268-KRegulation FD disclosure· period Oct 21, 2026Document · Index
Oct 20, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 20, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 16, 2026Document · Index
Oct 20, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 16, 2026Document · Index
Oct 5, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026Document · Index
Oct 5, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Oct 5, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026Document · Index
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026Document · Index
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026Document · Index
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026Document · Index
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026Document · Index
Sep 30, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 22, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 20, 2026Document · Index
Sep 22, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 20, 2026Document · Index
Sep 18, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 16, 2026Document · Index
Sep 18, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 16, 2026Document · Index
Sep 18, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 16, 2026Document · Index
Sep 18, 20268-KShareholder vote results· period Sep 16, 2026Document · Index
Sep 18, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 16, 2026Document · Index
Sep 18, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 16, 2026Document · Index
Sep 18, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 16, 2026Document · Index
Sep 17, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 15, 2026Document · Index
Sep 17, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 15, 2026Document · Index
Sep 15, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 15, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 14, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 10, 2026Document · Index
Sep 14, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 10, 2026Document · Index
Sep 14, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 10, 2026Document · Index
Sep 14, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 10, 2026Document · Index
Sep 14, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 10, 2026Document · Index
Sep 10, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 8, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 8, 20268-KRegulation FD disclosure· period Sep 8, 2026Document · Index
Sep 1, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 28, 2026Document · Index
Aug 28, 2026144Notice of proposed sale of securitiesDocument · Index

Insider filing activity

99 Form 4 filings appear in Roivant Sciences Ltd.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001635088 and XBRL company facts. Roivant Sciences Ltd. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.